Safety of Immune Checkpoint Inhibitors in Cancer Patients With Preexisting Autoimmune Vasculitis.

Key Points

• The aim is to evaluate the safety of immune checkpoint inhibitors in cancer patients who have preexisting autoimmune vasculitis.
• Observational assessment of cancer patients receiving immune checkpoint inhibitors
• Monitoring for disease flares during therapy
• Evaluation of flare management outcomes
• One-third of patients experienced a disease flare during treatment
• One fatal case was reported
• Most patients had favorable outcomes with effective management of flares

Abstract